Zai Lab Ltd (ZLAB) - Total Assets
Based on the latest financial reports, Zai Lab Ltd (ZLAB) holds total assets worth $1.10 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Zai Lab Ltd (ZLAB) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Zai Lab Ltd - Total Assets Trend (2015–2025)
This chart illustrates how Zai Lab Ltd's total assets have evolved over time, based on quarterly financial data. Explore ZLAB long-term investment intensity to see how much of total assets are deployed in long-term investments.
Zai Lab Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Zai Lab Ltd's total assets of $1.10 Billion consist of 86.9% current assets and 13.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.0% |
| Accounts Receivable | $106.12 Million | 9.1% |
| Inventory | $74.75 Million | 6.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $76.14 Million | 6.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Zai Lab Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Zai Lab Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zai Lab Ltd's current assets represent 86.9% of total assets in 2025, a decrease from 94.9% in 2015.
- Cash Position: Cash and equivalents constituted 58.0% of total assets in 2025, down from 94.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 9.1% of total assets.
Zai Lab Ltd Competitors by Total Assets
Key competitors of Zai Lab Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Zai Lab Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.40 | 3.26 | 9.33 |
| Quick Ratio | 2.19 | 3.09 | 9.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $551.75 Million | $722.06 Million | $1.61 Billion |
Zai Lab Ltd - Advanced Valuation Insights
This section examines the relationship between Zai Lab Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.15 |
| Latest Market Cap to Assets Ratio | 1.71 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | $1.17 Billion |
| Market Capitalization | $2.01 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Zai Lab Ltd's assets above their book value (1.71x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Zai Lab Ltd's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zai Lab Ltd (2015–2025)
The table below shows the annual total assets of Zai Lab Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.17 Billion | -1.13% |
| 2024-12-31 | $1.19 Billion | +14.42% |
| 2023-12-31 | $1.04 Billion | -15.07% |
| 2022-12-31 | $1.22 Billion | -24.21% |
| 2021-12-31 | $1.61 Billion | +24.07% |
| 2020-12-31 | $1.30 Billion | +265.37% |
| 2019-12-31 | $355.15 Million | +17.61% |
| 2018-12-31 | $301.99 Million | +20.97% |
| 2017-12-31 | $249.63 Million | +180.78% |
| 2016-12-31 | $88.91 Million | +537.79% |
| 2015-12-31 | $13.94 Million | -- |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more